Hormonal
A 12-week treatment with dulaglutide (1.5 mg weekly) does not improve long-term smoking abstinence rates compared to placebo when used as an adjunct to standard cessation therapy.
If you are trying to quit smoking, taking dulaglutide (Trulicity) alongside standard treatment (like Chantix/varenicline) will not increase your chances of staying smoke-free compared to standard treatment alone. Do not expect dulaglutide to help you quit smoking.
Dulaglutide does not improve long-term smoking abstinence... The point prevalence abstinence rates declined from almost two thirds of all participants at week 12 to 43% (54/127) in the dulaglutide and 41% (52/128) in the placebo group at week 24 and to 32% (41/127) and 32% (41/128) at 52, respectively.
Why this rating
Single-centre, randomised, double-blind, placebo-controlled, parallel group trial with 255 participants and 1-year follow-up.
Source
Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial
H Lüthi et al. · EClinicalMedicine · 2024
DOI 10.1016/j.eclinm.2024.102429
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →